Barclays Upgrades Sagimet Biosciences to Overweight from Equal-Weight
Fintel reports that on September 9, 2026, Barclays upgraded their outlook for Sagimet Biosciences (NASDAQGM:SGMT) from Equal-Weight to Overweight. This rating action follows the firm's prior action on January 28, 2026, when Barclays initiated coverage on the company with an Equal-Weight rating.
Sagimet Biosciences Inc., based in the United States, operates within the biotechnology industry, focusing primarily on the development of novel therapies for diseases with unmet medical needs, including metabolic and liver diseases. A key project for Sagimet Biosciences is the development of its leading compound, TVB-2640, which targets the fatty acid synthase enzyme implicated in various metabolic pathways. This investigational drug has shown potential in addressing conditions such as nonalcoholic steatohepatitis (NASH), which is a severe liver condition lacking effective treatment options.
Prior to this rating action, the stock closed at $10.71 on September 8, 2026. The company's stock price has experienced a price change of +2.00% over one week, relative to a baseline close of $10.50 on September 1, 2026. Over a one-month period, the price change was +18.21% from a baseline close of $9.06 on August 7, 2026.
As of August 28, 2026, the current consensus target mean for the stock is $29.17, with a median target of $29.07, representing an implied change of +172.38%. This is a revision of +8.48% from the prior consensus target mean of $26.89 recorded on August 4, 2026. In the recommendation period ending September 1, 2026, the aggregate analyst recommendations consisted of 6 strong buy, 10 buy, 2 hold, 0 sell, and 0 strong sell ratings. This total of 18 recommendations represents 88.9% positive, 11.1% hold, and 0.0% negative ratings, which is unchanged from the prior recommendation period on August 1, 2026.
Other recent analyst actions include HC Wainwright & Co. reiterating a Buy rating on August 25, 2026. Citizens maintained a Market Outperform rating on August 14, 2026, and Canaccord Genuity maintained a Buy rating on August 12, 2026.
On August 11, 2026, Sagimet Biosciences reported its latest earnings, with an actual EPS of -0.26 compared to an estimated EPS of -0.2511. Both actual and estimated revenues were $0.00. In its Form 10-Q filing dated August 11, 2026, the company reported that as of June 30, 2026, it had an accumulated deficit of $371.0 million and cash, cash equivalents and marketable securities of $257.6 million. The filing also noted that in August 2025, the company entered into a Sales Agreement with Leerink Partners LLC to establish an at-the-market offering through which the company may sell, from time to time at its sole discretion, up to $75.0 million shares of its Series A. The company's principal executive offices are located at 950 Tower Lane, Suite 1500, Foster City, CA 94404, as confirmed in a Form 8-K filing dated August 13, 2026.
Recent analyst actions
| Date | Analyst | Prior | Latest recommendation | Action |
|---|---|---|---|---|
| September 9, 2026 | Barclays | Equal-Weight | Overweight | upgrade |
| August 25, 2026 | HC Wainwright & Co. | Buy | Buy | reiterated |
| August 14, 2026 | Citizens | Market Outperform | Market Outperform | maintained |
| August 12, 2026 | Canaccord Genuity | Buy | Buy | maintained |
Fintel is one of the most comprehensive investing research platforms available to individual investors, traders, financial advisors, and small hedge funds.
Our data covers the world, and includes fundamentals, analyst reports, ownership data and fund sentiment, options sentiment, insider trading, options flow, unusual options trades, and much more. Additionally, our exclusive stock picks are powered by advanced, backtested quantitative models for improved profits.
This story originally appeared on Fintel.